{"entity":{"id":"myosin-therapeutics","kind":"company","name":"Myosin Therapeutics","aka":[],"tldr":"Myosin Therapeutics makes a tablet that blocks non-muscle myosin II, a motor protein cancer cells use to move, invade and divide. Its first trial is in people newly diagnosed with glioblastoma, alongside standard radiotherapy.","summary":"Myosin Therapeutics, Inc. is a privately held, clinical-stage company at 130 Scripps Way, Jupiter, Florida, founded by Courtney Miller, Patrick Griffin and Theodore Kamenecka on work from Scripps Research, which develops small molecules against molecular motor proteins. MT-125 is an oral, brain-penetrant dual inhibitor of non-muscle myosin IIA and IIB (NMIIA is encoded by MYH9); it holds FDA Orphan Drug designation for malignant gliomas and Fast Track designation for glioblastoma. The phase 1/2 STAR-GBM study (NCT07185880) with Mayo Clinic and NCI support tests MT-125 with standard radiotherapy in newly diagnosed MGMT-unmethylated glioblastoma, with first patient dosing announced on 19 May 2026; a second phase 1/2 study with chemoradiation in MGMT-methylated glioblastoma (NCT07604285) was registered in May 2026. The company also lists acute myeloid leukaemia and pancreatic cancer as expansion settings, a second oncology molecule MT-228, and MT-110 for stimulant use disorder. It reports a USD 4.5 million NCI SBIR Phase IIB Bridge Award (August 2025), a USD 2 million Florida Cancer Innovation Fund grant (March 2026) and a second seed round of over USD 3 million (February 2025). Its first registered cancer trial, NCT07185880, was posted on ClinicalTrials.gov in September 2025.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.myosintherapeutics.com/"},{"label":"ClinicalTrials.gov: phase 1/2 trial of MT-125 with chemoradiation in MGMT-methylated glioblastoma (NCT07604285)","url":"https://clinicaltrials.gov/study/NCT07604285"},{"label":"STAR-GBM first patient dosed, 19 May 2026","url":"https://myosintherapeutics.com/news-detail.php?id=25"}],"tags":[],"related":[],"cancers":["glioblastoma"],"sections":["targeted-therapy"],"technologies":[],"targets":["myh9"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07185880"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Read on 29 October 2026: myosintherapeutics.com about, pipeline and news pages and the 19 May 2026 STAR-GBM release. Founding year not stated on the company website."," MT-125 is a small-molecule motor-protein inhibitor; no OnCo technology record matches it, so none is linked. The myh9 target covers NMIIA only; NMIIB (MYH10) has no record.","Trial facts from ClinicalTrials.gov records NCT07185880 and NCT07604285, read on 29 October 2026."],"hq":"Jupiter, FL","country":"US","companyType":"biotech","website":"https://www.myosintherapeutics.com/","stage":"startup","investors":[],"funding":[{"round":"Seed","year":2025,"source":"https://www.myosintherapeutics.com/news-updates.php","note":"Second seed round, described by the company as raising over USD 3 million; exact amount not stated."},{"round":"Grant","year":2025,"amountUsd":4500000,"source":"https://www.myosintherapeutics.com/news-updates.php","note":"NCI SBIR Phase IIB Bridge Award for the MT-125 glioblastoma trial."},{"round":"Grant","year":2026,"amountUsd":2000000,"source":"https://www.myosintherapeutics.com/news-updates.php","note":"Casey DeSantis Florida Cancer Innovation Fund, Florida Department of Health, for the STAR-GBM trial."}]},"route":"/companies/myosin-therapeutics/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"target":[{"id":"myh9","kind":"target","name":"MYH9","route":"/targets/myh9/"}],"trial":[{"id":"nct07185880","kind":"trial","name":"A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients","route":"/trials/nct07185880/"}]}}